- Home
- KTF vs GNLX Comparison
KTF vs GNLX Comparison
Compare KTF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- GNLX
- Stock Information
- Founded
- KTF 1988
- GNLX 2001
- Country
- KTF United States
- GNLX United States
- Employees
- KTF N/A
- GNLX N/A
- Industry
- KTF Finance Companies
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KTF Finance
- GNLX Health Care
- Exchange
- KTF Nasdaq
- GNLX Nasdaq
- Market Cap
- KTF 384.3M
- GNLX 103.6M
- IPO Year
- KTF N/A
- GNLX 2023
- Fundamental
- Price
- KTF $9.47
- GNLX $2.27
- Analyst Decision
- KTF
- GNLX Strong Buy
- Analyst Count
- KTF 0
- GNLX 4
- Target Price
- KTF N/A
- GNLX $18.25
- AVG Volume (30 Days)
- KTF 103.3K
- GNLX 141.5K
- Earning Date
- KTF 01-01-0001
- GNLX 11-14-2024
- Dividend Yield
- KTF 3.54%
- GNLX N/A
- EPS Growth
- KTF N/A
- GNLX N/A
- EPS
- KTF 0.39
- GNLX N/A
- Revenue
- KTF N/A
- GNLX $8,000.00
- Revenue This Year
- KTF N/A
- GNLX N/A
- Revenue Next Year
- KTF N/A
- GNLX N/A
- P/E Ratio
- KTF $23.10
- GNLX N/A
- Revenue Growth
- KTF N/A
- GNLX N/A
- 52 Week Low
- KTF $7.40
- GNLX $1.60
- 52 Week High
- KTF $9.12
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- KTF 21.65
- GNLX 38.68
- Support Level
- KTF $9.95
- GNLX $2.13
- Resistance Level
- KTF $10.10
- GNLX $2.80
- Average True Range (ATR)
- KTF 0.09
- GNLX 0.20
- MACD
- KTF -0.06
- GNLX -0.04
- Stochastic Oscillator
- KTF 12.50
- GNLX 14.21
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-end, diversified investment management company. The investment objective is to provide high current income exempt from federal income tax by investing in a diversified portfolio of investment-grade tax-exempt securities. Its products include ETFs, Mutual Funds, Closed-End-Funds, Money Market Funds, and others.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.